How many amino acids does a nonapeptide have?

A nonapeptide has nine amino acids joined by eight peptide bonds in linear form. In cyclic nonapeptides like oxytocin and vasopressin, an intramolecular disulfide bond between two cysteine residues creates the ring structure; the backbone peptide bond count remains eight, but the disulfide bridge adds a covalent constraint that profoundly alters the molecule's three-dimensional geometry.

Is a nonapeptide an oligopeptide?

Yes. Oligopeptides are conventionally defined as peptides containing 2 to 20 amino acids. A nonapeptide, with nine amino acid residues, falls within this range and is classified as an oligopeptide. The major hormonal nonapeptides (oxytocin, vasopressin) are structurally oligopeptides that happen to have evolved into fundamental endocrine and neurological signaling molecules.

What Is a Nonapeptide? Definition & Examples

Creator: Superpower
Published: 2026-04-23

Key Takeaways

The definition: Nine amino acid residues linked by eight peptide bonds, which places every nonapeptide inside the oligopeptide class of 2 to 20 residues; in the cyclic forms, a disulfide bridge adds a further, non-peptide covalent link.
The canonical human pair: Oxytocin and arginine vasopressin are cyclic nine-residue hormones that differ at only two positions yet govern unrelated physiology.
Not every nonapeptide is cyclic: Bradykinin is a linear nine-residue peptide that raises vascular permeability and causes vasodilation.
Two meanings of one word: "Nonapeptide" is a size class, while "nonapeptide-1" is a single synthetic cosmetic ingredient regulated for appearance-level claims only.
Approved medicines exist in this class: Oxytocin is FDA-approved for medically indicated labor induction and for controlling postpartum bleeding, and vasopressin for vasodilatory shock, both prescription-only.
Measurement: Plasma oxytocin and vasopressin are research assays, not routine bloodwork.

What Is a Nonapeptide?

A nonapeptide is a peptide comprising nine amino acid residues (nona, Latin for ninth; peptós, Greek for digested) linked by eight peptide bonds in linear form, formed through condensation reactions that release one water molecule per bond. It belongs to the oligopeptide size class (2–20 amino acids); the endogenous cyclic nonapeptides sit near 1000 daltons, with oxytocin at about 1007 daltons and arginine vasopressin at about 1084 daltons. Cyclization via disulfide bridging slightly reduces molecular mass (loss of 2 hydrogens) rather than increasing it. In humans, the principal biological nonapeptides (oxytocin and arginine vasopressin) are cyclic: the disulfide bond between Cys1 and Cys6 closes the ring and imposes a conformational structure that is essential for receptor recognition. That disulfide links two cysteine side chains rather than adding a ninth peptide bond, so the ring closes through a side-chain bridge, not by joining the chain's two ends. Oxytocin is classed as a nonapeptide of the neurohypophyseal protein family, with both central and peripheral physiological roles.

Nonapeptide vs. nonapeptide-1: two meanings of one word

"Nonapeptide" names a size class: any peptide nine amino acids long, the endogenous hormones oxytocin and arginine vasopressin included. "Nonapeptide-1" names a single synthetic molecule, a cosmetic ingredient regulated for appearance-level claims only. Different molecules, different routes into the body, different evidence bases behind them.

How a nonapeptide forms structurally

Eight condensation reactions link nine amino acids, generating eight amide bonds and releasing eight water molecules in the linear form. For the biologically dominant cyclic nonapeptides, two cysteine residues at positions 1 and 6 undergo oxidative coupling to form a disulfide bond after the linear chain is assembled. This post-translational modification converts a linear nonapeptide into a cyclic structure with defined secondary structure. Oxytocin is the textbook case: a cyclic nonapeptide with an intramolecular disulfide bond formed between its two cysteine residues. The C-terminal glycine residue is amidated (Gly-NH₂) rather than left as a free carboxylate, a further post-translational modification carried by both oxytocin and vasopressin.

How a nonapeptide differs from adjacent peptide sizes

Moving from an octapeptide (8 AAs) to a nonapeptide adds one residue and one bond, but the most important structural transition in this size neighborhood is the cyclization that defines oxytocin and vasopressin, a feature not driven by peptide count alone but by specific cysteine placement that enables disulfide bridging. Moving up one step to a decapeptide (10 AAs) spans both endogenous signaling peptides and linear synthetic cosmetic sequences such as decapeptide-12. The useful contrast is therefore not the extra residue but the architecture of the best-studied molecules: the canonical nonapeptide hormones are cyclic, while the decapeptides most often described are linear.

| Peptide class | Amino acids | Peptide bonds | Size classification | Example molecule | Primary biological role | |---|---|---|---|---|---| | Dipeptide | 2 | 1 (linear) | Oligopeptide | Carnosine (β-Ala-His) | pH buffering, antioxidant in muscle and brain | | Tetrapeptide | 4 | 3 (linear) | Oligopeptide | Tuftsin (Thr-Lys-Pro-Arg) | Innate immune stimulation (phagocytosis) | | Pentapeptide | 5 | 4 (linear) | Oligopeptide | Met-enkephalin (Tyr-Gly-Gly-Phe-Met) | Opioid receptor binding, pain modulation | | Nonapeptide | 9 | 8 (plus a disulfide bridge in the cyclic forms) | Oligopeptide | Oxytocin, arginine vasopressin | Hormonal signaling: social behavior, parturition, renal water regulation, cardiovascular tone | | Decapeptide | 10 | 9 (linear) | Oligopeptide | Decapeptide-12 | Tyrosinase inhibition, reducing melanin synthesis (cosmetic brightening) | | Oligopeptide (general) | 2–20 | 1–19 | Oligopeptide | All of the above plus insulin C-peptide fragments | Highly variable across the size range: signaling, antimicrobial, cosmetic, and nutritional applications |

Peptide bond counts above are for the linear backbone; cyclic variants add a disulfide bridge, which changes conformation without changing the peptide bond count.

Examples of Nonapeptides in Human Biology

The nonapeptide size class is anchored by two deeply conserved hormonal signaling molecules in vertebrate biology, and it reaches well past them into inflammation, bone, and comparative physiology.

Oxytocin

Oxytocin (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂, cyclic 1-6 disulfide) is a cyclic nonapeptide synthesized in magnocellular neurons of the paraventricular and supraoptic nuclei of the hypothalamus and released from the posterior pituitary. Its roles split across two levels: centrally it modulates maternal, sexual, social and stress-related behavior, while its peripheral actions center on smooth muscle contraction, particularly within the reproductive tracts. A single-transcript-level atlas has mapped oxytocin and its receptor across the whole mouse brain, illuminating the anatomical and molecular basis for this nonapeptide's behavioral complexity. Oxytocin is also FDA-approved for medically indicated labor induction and to control postpartum bleeding, though it is not indicated for elective induction of labor, making it one of the few endogenous nonapeptides with a direct clinical pharmaceutical application. Plasma oxytocin levels are not standard clinical bloodwork, but the hormonal systems it interacts with (cortisol, prolactin, estradiol) are routinely measured.

Arginine vasopressin (AVP)

Arginine vasopressin (Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH₂), also called antidiuretic hormone (ADH), is the second canonical human nonapeptide. It differs from oxytocin at only two positions (Ile3/Phe3 and Leu8/Arg8) yet governs entirely different physiological functions: renal water reabsorption via V2 receptors in the collecting duct, arterial vasoconstriction via V1 receptors, and regulation of the endocrine stress response. Vasopressin injection is FDA-approved to raise blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Terlipressin (Terlivaz) is FDA-approved for improving kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. Both are prescription-only, hospital-administered agents. Plasma sodium, serum osmolality, and urine osmolality are the clinical markers that reflect AVP-regulated water balance in standard practice.

Oxytocin vs. vasopressin: two residues apart

| Feature | Oxytocin | Arginine vasopressin | |---|---|---| | Amino acid sequence | Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂ | Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH₂ | | Differing positions | Ile at position 3, Leu at position 8 | Phe at position 3, Arg at position 8 | | Receptor family | Oxytocin receptor (OXTR) | V1 vascular, V2 renal | | Primary target tissue | Uterus, mammary gland, brain | Kidney collecting duct, vascular smooth muscle | | Main physiological effect | Parturition, lactation, social bonding | Renal water reabsorption, vasoconstriction | | FDA-approved drug form | Oxytocin injection for medically indicated labor induction | Vasopressin injection for vasodilatory shock |

Bradykinin: the nonapeptide that is not a hormone

Not every nine-residue peptide is a cyclic hormone. Bradykinin (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) is the third major human nonapeptide, and it is linear: no disulfide bridge, so no ring. Bradykinin acts as an inflammatory mediator rather than an endocrine signal, raising vascular permeability and causing vasodilation, and it participates in pain signaling.

Nonapeptides in comparative and evolutionary biology

The oxytocin-vasopressin nonapeptide family is one of the most deeply conserved signaling systems known in vertebrate biology. In non-mammalian vertebrates, arginine vasotocin (AVT) and mesotocin fulfill the roles of vasopressin and oxytocin, respectively (isotocin standing in for mesotocin in teleost fish), and all are cyclic nonapeptides with the same core architecture. Brain distributions of the oxytocin-like and vasopressin-like peptides are fundamentally similar across all vertebrates, while their receptor distributions are highly species-specific. In a biparental cichlid fish, brain vasotocin is linked to parental care, further documenting nonapeptide involvement in social behavior across highly divergent species.

Arginine vasotocin and pleiotropic tissue effects

Beyond classical endocrine roles, vasopressin-family nonapeptides act on non-renal tissues. In vitro patch-clamp work finds that AVP facilitates osteoblast calcium currents, pointing to AVP activity in bone cells beyond its classical kidney and cardiovascular functions. Structure-activity relationships within the nonapeptide family illustrate how small residue substitutions in these nine-residue peptides can separate antidiuretic activity from sodium and potassium excretion, an effect traced in rats to different vasopressin receptor subtypes.

Examples of Nonapeptides in Therapeutics and Cosmetics

Beyond the endogenous hormones, nonapeptide-length sequences have been applied in two very different arenas: cosmetic skin brightening and prescription pharmaceuticals.

Nonapeptide-1 (cosmetic skin brightening)

Nonapeptide-1 (INCI: Nonapeptide-1) is a synthetic nine-amino-acid sequence designed to inhibit melanin synthesis. It carries the trade name Melanostatine-5, CAS 158563-45-2, and the sequence Met-Pro-D-Phe-Arg-D-Trp-Phe-Lys-Pro-Val-NH₂. Its proposed mechanism involves competition with alpha-melanocyte-stimulating hormone (alpha-MSH) at the melanocortin 1 receptor (MC1R), an approach distinct from the more common cosmetic strategy of blocking the tyrosinase enzyme directly, the route decapeptide-12 takes. The biological context for this inhibition involves the agouti signal protein, which naturally competes with alpha-MSH at MC1R to switch melanin synthesis from eumelanin to phaeomelanin; the bioactive motifs behind that competition are characterized, establishing the natural receptor competition biology that cosmetic nonapeptide-1 is engineered to replicate. In an open-label evaluation of a decapeptide-12 regimen that also included a glycolic-acid moisturizer and a broad-spectrum sunscreen, photodamage grading improved in the 13 subjects who completed it (an uncontrolled study of a different peptide working through a different mechanism). Direct in vivo human clinical-trial evidence for nonapeptide-1 specifically remains limited. Under FDA cosmetics law, nonapeptide-1 is regulated for appearance-level claims only.

Oxytocin as a pharmaceutical nonapeptide

Oxytocin is an FDA-approved nonapeptide medication given by intravenous infusion to induce or reinforce medically indicated labor, and by infusion or intramuscular injection to control postpartum uterine bleeding. Its clinical evidence base is extensive, built on decades of obstetric practice in those indications. Findings in autism spectrum disorder populations remain preliminary and translational; this use is not FDA-approved as of April 2026, and intranasal oxytocin remains investigational for psychiatric indications. No intranasal oxytocin product is currently FDA-approved in the United States; compounded intranasal oxytocin preparations used in research settings are investigational and not FDA-authorized for therapeutic use. The nasal delivery route is scientifically significant: in rats, most brain oxytocin arrived directly from the nasal cavity rather than through the bloodstream.

Nonapeptide combination formulations in cosmetics

Cosmetic formulations typically stack several peptides rather than rely on one. One tested eye formulation combined two peptide actives: palmitoyl tripeptide-1 alongside palmitoyl tetrapeptide-7 and two non-peptide ingredients, though that trial measured skin-quality endpoints rather than pigmentation. Signal peptides of this kind are a promising cosmetic ingredient class. Marine-derived peptides and other bioactives are being explored for similar cosmetic endpoints, including anti-hyperpigmentation applications.

Can Nonapeptide Levels Be Measured?

Nonapeptide levels are not measured in routine bloodwork. Plasma oxytocin is a research assay, and extraction and non-extraction immunoassays disagree by two orders of magnitude, which is why published oxytocin values are difficult to compare across studies. Circulating arginine vasopressin is unstable and hard to assay directly, so research and specialist diagnostic settings rely on copeptin, the stable fragment released alongside vasopressin, as the surrogate measure. Oxytocin, vasopressin, and copeptin are research and specialist diagnostic assays rather than routine panel tests, and none of them appear on Superpower's panels.

Why Nonapeptides Matter for Your Health

Nonapeptides operate at the center of two major biological domains: hormonal neurophysiology (oxytocin and vasopressin) and cosmetic skin biology (nonapeptide-1). From a health biology perspective, the vasopressin-oxytocin axis influences cardiovascular regulation, renal water balance, stress response, and social behavior: all systems with measurable biomarker correlates. The evolutionary conservation of these nine-residue structures across vertebrate phylogeny (illustrated by the regulatory role of arginine vasotocin on the avian kidney) reflects how essential this size class is to fundamental physiology.

For the cosmetic application of nonapeptide-1, the relevant biological context involves the melanocortin signaling axis, skin inflammatory environment, and systemic nutrient status. Alpha-MSH (a 13-amino-acid melanocortin, and the upstream signal that nonapeptide-1 competes against) is released by keratinocytes after UV exposure, which is what sets the competitive environment nonapeptide-1 is designed to enter. Baseline hs-CRP reads systemic inflammatory burden rather than melanocortin signaling, so it gives general background context, not a measure of alpha-MSH activity. The innate immune activity that intersects with melanocortin biology shows up instead in the white-cell and inflammatory markers a standard immune workup covers.

Measuring biology before interpreting any compound's effect is central to how Superpower works. In the nonapeptide context (whether the focus is hormonal health or cosmetic skin biology), a baseline reading is the reference point that makes change visible.

Which Biomarkers Are Relevant When Exploring Nonapeptide Biology?

Nonapeptides span two biological domains (hormonal physiology and cosmetic skin science) with different relevant marker sets for each.

Plasma sodium: The primary clinical indicator of arginine vasopressin (AVP) activity. Vasopressin governs renal water reabsorption; serum sodium reflects the net result of that regulation. Hyponatremia or hypernatremia can signal disturbed AVP-driven water balance.
Cortisol (AM): Across laboratory stress tasks, intranasal oxytocin administration showed no significant overall effect on cortisol, with attenuation mainly under strong HPA stimulation and in clinical populations. Morning cortisol reflects adrenal axis activity and provides context for the stress-neuroendocrine environment in which oxytocin signaling operates.
High-sensitivity CRP (hs-CRP): Systemic inflammatory marker. For the cosmetic skin application context, hs-CRP reflects overall inflammatory load.
White blood cells (WBC) with differential: Innate immune cell patterns describe the background inflammatory environment rather than nonapeptide signaling itself. The WBC differential offers a broad immune baseline.
Ferritin: Iron storage marker. Iron deficiency can produce pallor, a change in skin appearance distinct from melanin-driven pigmentation; ferritin is a useful baseline marker before attributing a change in skin tone to MC1R axis activity alone.
Vitamin B12: Deficiency has been linked to skin hyperpigmentation at the case-report level. Monitoring vitamin B12 provides context for non-UV sources of skin pigmentation changes that nonapeptide-1 and other MC1R-targeting cosmetics would not address.
Prolactin: Oxytocin and prolactin interact in the regulation of lactation; prolactin levels are part of the hormonal context for oxytocin signaling in reproductive and social biology.

See the Markers Nonapeptide Signaling Touches With a Superpower Panel

No Superpower panel measures oxytocin or arginine vasopressin, so what you can see is the physiology those nonapeptides act on. The Superpower Baseline Panel includes sodium, cortisol, high-sensitivity CRP, white blood cells, and ferritin among the 100+ biomarkers it measures, so the systems nonapeptide signaling touches become something you can watch over time rather than infer. Vitamin B12 and prolactin are available through the Advanced Blood Panel add-on rather than the baseline panel. Sodium, cortisol, and inflammation sit inside the wider set of hormone and inflammation biomarkers tracked across the platform. Start with Superpower and build a baseline worth returning to.

Measured by FDA-cleared clinical laboratory methods; used to aid clinician evaluation; not a stand-alone diagnosis.

Oxytocin injection, vasopressin injection, and terlipressin are prescription medications named here for educational context only. Superpower does not prescribe or dispense these medications; obtain them only through a licensed healthcare provider. Compounded intranasal oxytocin is not FDA-approved and is not offered by Superpower for the investigational uses described here.

Frequently Asked Questions

A nonapeptide is a peptide made of nine amino acid residues linked by eight peptide bonds, with a disulfide bridge closing a ring in the cyclic forms. It belongs to the oligopeptide class. The canonical biological nonapeptides are oxytocin and arginine vasopressin (AVP), both cyclic nine-residue peptides produced in the hypothalamus. Nonapeptide-1 is a synthetic cosmetic nonapeptide investigated for skin-brightening applications.

Oxytocin (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂, cyclic) is the primary social bonding and parturition hormone; arginine vasopressin (Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH₂, cyclic) regulates renal water reabsorption and vascular tone. In non-mammalian vertebrates, arginine vasotocin (AVT) and mesotocin fill the same roles (isotocin replacing mesotocin in teleost fish) and are also cyclic nonapeptides. Nonapeptide-1 is a synthetic cosmetic analogue investigated as a MC1R pathway modulator for skin brightening. Bradykinin is a third human nonapeptide, and unlike oxytocin and vasopressin it is linear rather than cyclic.

A nonapeptide has nine amino acids and eight peptide bonds; a decapeptide has ten amino acids and nine. The most significant difference for human biology is contextual rather than purely structural: the canonical biological nonapeptides (oxytocin, vasopressin) are cyclic, while most studied decapeptides are linear. The disulfide bridge between Cys1 and Cys6 in oxytocin and vasopressin creates a ring that is central to their receptor-binding geometry and distinguishes the nonapeptide hormone family from linear decapeptide chemistry.

Nonapeptide-length sequences are generated during protein hydrolysis (for example, during digestion of casein, whey, and fish proteins). Absorption of intact nine-residue chains is limited: the PEPT1 transporter handles di- and tripeptides preferentially, and larger oligopeptides require alternative pathways. That capacity also shifts with inflammatory signaling, since IFN-γ upregulates PEPT1 expression; nonapeptides at nine residues exceed PEPT1's well-characterized di-/tripeptide specificity, so dietary nonapeptide uptake as intact chains is minimal.

Endogenous nonapeptides (oxytocin and vasopressin) are present in the body naturally and are well-characterized physiologically. Oxytocin and vasopressin (including the vasopressin analog terlipressin) are FDA-approved prescription medications used in specific clinical indications: labor and postpartum care for oxytocin; vasodilatory shock for vasopressin; hepatorenal syndrome for terlipressin. Each carries its own FDA-approved labeling and risk profile. The oxytocin and terlipressin labels carry boxed warnings: the oxytocin label states it is not indicated for elective induction of labor, and the terlipressin label warns of serious or fatal respiratory failure. All three are prescription-only and are typically administered in obstetric or hospital/ICU contexts rather than self-administered; whether any of them is appropriate for a given patient is a decision for the prescribing clinician. Synthetic cosmetic nonapeptides such as nonapeptide-1 are regulated under FDA cosmetics law, which involves no FDA pre-market approval; responsibility for substantiating the safety of the finished product sits with its manufacturer. Individual tolerability for any formulation depends on concentration and skin characteristics.

Nonapeptide-1 is a synthetic cosmetic ingredient proposed to reduce melanin synthesis by competing with alpha-MSH at the melanocortin 1 receptor (MC1R). The proposed mechanism is that MC1R competition reduces downstream signaling that activates tyrosinase and drives melanin production; human clinical evidence for nonapeptide-1 at this level remains limited. Under FDA cosmetics law, claims are limited to appearance-level outcomes: a formulation may be described as supporting the appearance of more even skin tone, not as treating a pigmentation disorder.

What Is a Nonapeptide? Definition and Examples

Key Takeaways

What Is a Nonapeptide?